BlackRock Investment Management’s Lisata Therapeutics LSTA Stock Holding History

BlackRock Investment Management’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-33	Closed	-$3K	–	3972
2016 Q2	$3K	Sell	33 -25	-43%	-$2.3K	﹤0.01%	3930
2016 Q1	$7K	Hold	58	–	–	﹤0.01%	3730
2015 Q4	$9K	Buy	58 +5	+9%	+$918	﹤0.01%	3713
2015 Q3	$12K	Buy	53 +2	+4%	+$502	﹤0.01%	3613
2015 Q2	$14K	Sell	51 -469	-90%	-$174K	﹤0.01%	3584
2015 Q1	$198K	Buy	520 +28	+6%	+$15.2K	﹤0.01%	3224
2014 Q4	$278K	Sell	492 -1	-0.2%	-$681	﹤0.01%	3196
2014 Q3	$409K	Buy	493 +14	+3%	+$12.3K	﹤0.01%	3078
2014 Q2	$469K	Buy	+479	New	+$466K	﹤0.01%	3072

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EGA

Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

BlackRock Investment Management's LSTA Position: Q3 2016 in Review

BlackRock Investment Management sold out of Lisata Therapeutics (LSTA) in Q3 2016, closing a stake of 33 shares — an estimated $3K sold.

BlackRock Investment Management first reported a position in LSTA in Q2 2014 and held it in 9 quarters. The position peaked at $469K in Q2 2014. 28 funds tracked by Wall St. Rank hold LSTA as of Q3 2016.

BlackRock Investment Management reported no remaining Lisata Therapeutics position as of Q3 2016 after selling out during the quarter.
BlackRock Investment Management sold 33 Lisata Therapeutics shares in Q3 2016, an estimated $3K.
BlackRock Investment Management first reported a position in Lisata Therapeutics in Q2 2014 and held it in 9 quarters.
BlackRock Investment Management's Lisata Therapeutics position peaked at $469K in Q2 2014.
28 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2016.

Based on BlackRock Investment Management's 13F filing for Q3 2016, filed 8 Nov 2016.